]>
IRCT20190817044547N1 IRCT 2019-10-01 Shahed University The Effect of Hab-o-Shefa Product on craving Reduction in Outpatients with Opioid Substance Use Disorder The Effect of Hab-o-Shefa Product on craving Reduction after Detoxification Phase in Outpatients with Opioid Substance Use Disorder 2019-09-22 anticipated 20 Complete https://irct.ir/trial/41628 interventional Randomization: N/A, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Supportive, Blinding description: Hab-o-Shefa Product and placebo were numbered by the third person. 3 Substance abuse. Intervention 1: Intervention group: The patients will receive daily oral 500 mg of Hab-o-Shefa Product for three months. Intervention 2: Control group: The patients will receive daily oral 500 mg of placebo for three months. Yes - There is a plan to make this available What will be shared: Clinical and psychological outcomes after the study When: 1400 To whom: Academic Researchers Conditions: Academic Researchers Where to obtain: web site, Email How to obtain: Academic Email Comments:
public Mohammad Bagher Saberi zafarghandi
Shahied Mansuri St, Niayesh St, Sattarkhan Ave
Tehran Iran (Islamic Republic of) 1445613111 +98 21 6655 1658 saberi.mb@iums.ac.ir Iran University of Medical Sciences scientific Yasha Fayaz Feizy
No. 31, 5th floor, Mahdi Building, Opposite Maryam Pharmacy, Bakhshdari Alley, Before Azadegan Bridge, North Taleghani
Karaj Iran (Islamic Republic of) 3155666473 +98 26 3221 9703 dr_yasha_fayaz@yahoo.com Iran University of Medical Sciences Iran (Islamic Republic of) All patients with opioid addiction according to the DSM V Reference Criteria who have not had other substance use disorders such as stimulants in the past year People who can answer questions and tests Blood pressure is lower than 14.9cm Hg; There is not history of major physical and mental illness There is an equal distribution on education, occupation, and marital status between samples. 15 years 60 years Male F11.2 Opioid dependence Rehabilitation Placebo Intervention group: The patients will receive daily oral 500 mg of Hab-o-Shefa Product for three months. Control group: The patients will receive daily oral 500 mg of placebo for three months. Craving after Detoxification Phase. Timepoint: At the baseline (before intervention) and monthly until end of study. Method of measurement: Obsessive Compulsive Drug use Scale questionnairy. Shahed University Approved 2018-10-29 Ethics committee of Shahed University No. 1471, Above Shiraz Opportunity Crossing, Kargar Shomali St., Enghelab Square Tehran Tehran Iran (Islamic Republic of)